X
<

Pfizer’s 2017 Performance in Review

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 4
Pfizer’s 2017 Performance in Review PART 4 OF 12

Behind Pfizer’s Internal Medicines in 2017

PFE’s Eliquis revenue trends

In 4Q17, Pfizer’s (PFE) Eliquis generated revenues of $710 million, which represented a ~46% rise on a YoY (year-over-year) basis and a 10% rise quarter-over-quarter. In 4Q17, in the US and outside the US (international markets), Eliquis reported revenues of $337 million and $333 million, respectively, compared with $264 million and $223 million in 4Q16, reflecting a rise of 43% and a rise of 49% on a YoY basis.

In fiscal 2017, Eliquis reported revenues of $2.5 billion, which reflected ~47% growth on a YoY basis. In 2017, in the US and international markets, Eliquis reported revenues of $1.4 billion and $966 million, respectively, reflecting ~47% and 48% growth on a YoY basis.

Behind Pfizer’s Internal Medicines in 2017

Interested in PFE? Don't miss the next report.

Receive e-mail alerts for new research on PFE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Eliquis is used to decrease the risk of stroke and systemic embolism in individuals with nonvalvular atrial fibrillation. Eliquis (apixaban) is also used for the prevention of deep vein thrombosis that might lead to a pulmonary embolism in individuals who underwent hip or knee replacement surgery.

Bristol-Myers Squibb (BMY) and Pfizer jointly commercialize Eliquis. Notably, Bristol-Myers Squibb generated revenues of $1.36 billion from the sales of Eliquis. In the marketplace, Eliquis competes with Johnson & Johnson’s (JNJ) Xarelto and Boehringer Ingelheim’s Pradaxa.

Chantix-Champix revenue trends

In 4Q17, Chantix-Champix reported revenues of $271 million, which represents a ~28% rise on a YoY basis. In 4Q17, in the US and in international markets, Chantix-Champix reported revenues of $200 million and $71 million, respectively, compared with $148 million and $63 million in 4Q16, reflecting ~35% and ~12% growth on a YoY basis.

In fiscal 2017, Chantix-Champix reported revenues of $997 million, which represents a ~18% YoY rise. In 2017, in the US and in international markets, Chantix reported revenues of 742 million and 255 million, respectively, compared with $597 million and $245 million in 2016, representing ~24% and ~4% growth on a YoY basis.

BMP2 and Toviaz revenue trends

In 2017, Pfizer’s BMP2 and Toviaz reported revenues of $261 million and $257 million, respectively, compared with $251 million and $258 million in 2016. In 2017, in the US and international markets, Toviaz reported revenues of $85 million and $173 million, respectively, compared with $99 million and $160 million in 2016.

In 4Q17, BMP2 and Toviaz reported revenues of $64 million and $70 million, respectively, compared with $76 million and $67 million in 4Q16. In 4Q17, in the US and in international markets, Toviaz reported revenues of $22 million and $48 million, respectively, compared with $27 million and $41 million in 4Q16.

Toviaz is used for the treatment of overactive bladders. In the marketplace, Toviaz’s competitors include Astellas Pharma’s Vesicare and Myrbetriq and Allergan’s (AGN) Enablex.

Continue to the next part of this series for a closer look at Pfizer’s Viagra and Lyrica in 4Q17 and 2017.

X

Please select a profession that best describes you: